Singapore markets close in 4 hours 20 minutes
Explore/

Largest 52-Week Gains

Largest 52-Week Gains

12.18k followers31 symbols Watchlist by Yahoo Finance

Follow this list to discover and track stocks with the greatest 52-week gain. These are stocks whose price has increased the most over the past 52 weeks (percent change). This list is generated daily, the gains are based on today's closing price and limited to the top 30 stocks that meet the criteria.

Curated by Yahoo Finance

Follow this list to discover and track stocks with the greatest 52-week gain. These are stocks whose price has increased the most over the past 52 weeks (percent change). This list is generated daily, the gains are based on today's closing price and limited to the top 30 stocks that meet the criteria.

Background

Yahoo Finance employs sophisticated algorithms to monitor and detect trends in the Global Financial Markets. We bring these insights to you in the form of watchlists.

Find other winning investment ideas with the Yahoo Finance Screener.

How are these weighted?

The stocks in this watchlist are weighted equally.

Performance

WatchlistChange today1-month return1-year returnTotal return
Largest 52-Week Gains-0.17%---
^GSPC+0.77%+4.70%+49.51%+4339.57%

31 symbols

SymbolCompany nameLast priceChange% changeMarket timeVolumeAvg vol (3-month)Market cap
NIONIO Inc.38.12-0.58-1.50%4:00 pm GMT-468.84M98.88M62.46B
CZRCaesars Entertainment, Inc.96.33+0.18+0.19%4:00 pm GMT-42.12M3.35M20.06B
PENNPenn National Gaming, Inc.104.12-2.57-2.41%4:00 pm GMT-42.96M5.17M16.29B
NVAXNovavax, Inc.179.74+3.47+1.97%4:00 pm GMT-42.14M4.29M13.28B
GMEGameStop Corp.158.36-11.90-6.99%4:00 pm GMT-49.36M45.43M11.09B
SIDCompanhia Siderúrgica Nacional7.58+0.25+3.41%4:00 pm GMT-47.48M3.99M10.69B
FVRRFiverr International Ltd.226.65-2.45-1.07%4:00 pm GMT-4377.72k1.17M8.12B
MSTRMicroStrategy Incorporated711+20.88+3.03%4:00 pm GMT-4344.68k908.47k6.82B
PACBPacific Biosciences of California, Inc.32.16-1.33-3.97%4:00 pm GMT-42.72M4.66M6.21B
UPWKUpwork Inc.47.96-0.76-1.56%4:00 pm GMT-4882.06k2.13M5.99B
SPWRSunPower Corporation29.71+0.33+1.12%4:00 pm GMT-42.59M7.49M5.12B
DQDaqo New Energy Corp.69.29+3.07+4.64%4:00 pm GMT-43.00M2.86M4.81B
MGNIMagnite, Inc.40.18+0.62+1.57%4:00 pm GMT-41.66M4.32M4.64B
AMRSAmyris, Inc.16.59+0.55+3.43%4:00 pm GMT-412.84M5.09M4.53B
SISilvergate Capital Corporation163.2+6.20+3.95%4:00 pm GMT-41.24M1.48M3.83B
JMIAJumia Technologies AG37.2-0.87-2.29%4:00 pm GMT-42.90M8.72M3.67B
BBBYBed Bath & Beyond Inc.30.03+0.40+1.35%4:00 pm GMT-42.79M11.37M3.64B
CWHCamping World Holdings, Inc.38.27+0.13+0.34%4:00 pm GMT-4699.93k1.43M3.39B
SIGSignet Jewelers Limited61.08+3.49+6.06%4:00 pm GMT-4734.68k1.11M3.20B
MIKThe Michaels Companies, Inc.21.97--4:00 pm GMT-41.85M5.94M3.11B
DNMRDanimer Scientific, Inc.34.36-2.71-7.31%4:00 pm GMT-42.04M2.59M3.03B
LOBLive Oak Bancshares, Inc.70.09+0.99+1.43%4:00 pm GMT-4153.82k375.25k3.00B
TIGRUP Fintech Holding Limited19.96+0.76+3.96%4:00 pm GMT-411.42M10.10M2.81B
ARAntero Resources Corporation9.19-0.40-4.17%4:00 pm GMT-46.96M9.31M2.77B
ACCDAccolade, Inc.47.18+0.37+0.79%4:00 pm GMT-41.05M1.03M2.76B
MTDRMatador Resources Company23.46-0.86-3.54%4:00 pm GMT-41.25M2.11M2.74B
SGRYSurgery Partners, Inc.45.45-0.59-1.28%4:00 pm GMT-4268.50k504.57k2.73B
OMIOwens & Minor, Inc.36.7-0.89-2.37%4:00 pm GMT-4546.52k1.29M2.70B
CALXCalix, Inc.41.45+0.98+2.42%4:00 pm GMT-4743.84k972.61k2.61B
CLNEClean Energy Fuels Corp.12.29-0.81-6.18%4:00 pm GMT-43.82M7.79M2.45B
  • 4 Undervalued Stocks To Watch For In April
    Benzinga

    4 Undervalued Stocks To Watch For In April

    EBay Inc (NASDAQ: EBAY), SunPower Corporation (NASDAQ: SPWR), Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Tupperware Brands Corporation (NYSE: TUP) are four stocks considered technically undervalued this month. Investors may seek out undervalued stocks to invest in for the long term, hoping the market eventually realizes the stock is trading lower than its actual value and makes an upward correction. How A Stock Is Deemed Undervalued: A stock is considered undervalued based on its price-to-earnings ratio (P/E). A stock's P/E is found by dividing the stock’s current share price by its earnings per share (EPS) over the past 12 months. A high P/E indicates the stock is trading above its value and could therefore be overvalued, while a low P/E means it is trading below its value and could therefore be overvalued. As an example, if a stock is trading at $40 and has an EPS of $4, it has a P/E ratio of 10, meaning that for every share investors purchase, they claim $10 in earnings. This is considered a low P/E and could indicate the stock is undervalued. Conversely, if a stock is trading at $40 per share and has an EPS of $1, it has a P/E ratio of 40 meaning that for every share investors purchase they claim only $1 in earnings. This is considered a high P/E and could indicate the stock is overvalued. Four Stocks That May Be Undervalued: EBay, a San Jose-based multinational e-commerce company, has a 12-month EPS of $7.89 ended Friday's trading at $62.47, giving it a P/E of 7.92. This may indicate it is undervalued. When eBay reported fourth-quarter earnings on Feb. 3, its revenue was up 28% to $2.9 billion, showing it may be going through a period of high growth. SunPower, a San Jose-based solar energy company, has a 12-month EPS of $2.48 and ended Friday's trading at $29.71, giving it a P/E ratio of 11.99. This may indicate it is undervalued. When SunPower reported fourth-quarter earnings on Feb. 17, the company said it had added 13,000 new customers. With the push for renewable energy, this may continue to grow, bringing the company increasing revenue. Regeneron, the Westchester County-based biotechnology company, has a 12-month EPS of $30.52 and ended Friday's trading at $475.17, giving it a P/E ratio of 15.57. This may indicate it is undervalued. When Regeneron reported its fourth-quarter results on Feb. 5 it had increased revenues by 30% compared to fourth-quarter 2019, showing sustained growth. Tupperware, an Orlando-based multi-level marketing company with an extensive home product line, has a 12-month EPS of $2.14 and ended Friday's trading at $27.02, giving it a P/E ratio of 12.63. This may indicate it is undervalued. When Tupperware released its fourth-quarter results on March 10, it said its global sales were up 17%, 20% in local currency, compared to the year prior. (Photo by Rhett Wesley on Unsplash) See more from BenzingaClick here for options trades from BenzingaHow This Psychedelic Company Could Lead A Turnaround For The Sector3 Pot Stocks Looking To Bounce© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • TipRanks

    New Leadership And Additional Capital Could Help Pacific Biosciences Deliver Major Revenue Growth

    For gene sequencing company Pacific Biosciences (PACB), also known as PacBio, regulators’ refusal to allow Illumina (ILMN) to buy the company may have been a blessing in disguise. Since Illumina abandoned its bid early in 2020, PacBio has changed up its senior management team, secured its funding needs from SoftBank Group (SFTBF), announced a major partnership with Invitae (NVTA), and seen the share price rise from under $5 to over $50, before settling down at $32.16. PacBio has always had good technology, but the company has struggled in the past to execute and deliver on the potential of that technology. With the latest iteration of the technology (the Sequel II system), former Illumina executive Christian Henry running the company, and increasing awareness of the potential of long-read genetic sequencing, the company now looks well-positioned to leverage that technology and deliver considerable revenue growth in the coming years. Funding Worries Have Faded Given its long-running string of operating losses and the fact that PacBio has never generated $100 million of revenue in a year, cash and liquidity have been an ongoing issue for PacBio, and were likely part of the reason why the company initially agreed to the Illumina deal. With few financing options outside of highly dilutive equity offerings, PacBio was essentially forced to underspend on R&D and SG&A, effectively undermining its own efforts to drive wider adoption of its systems and technology. The breakup agreement with Illumina helped ease some of the cash crunch and the appointment of Henry as CEO did improve sentiment, but the turning point was SoftBank’s decision to invest $900 million in the company through a convertible debt offering in February of this year. With an effective conversion price of $43.50/share (or around 20.7 million shares), PacBio was able to secure very cost-effective funding from a committed investor that will almost certainly see it through to positive free cash flow. Funding in hand, management intends to significantly expand the company, looking to “at least” double the number of sales representatives during 2021 and advancing a host of R&D projects ranging from future system development to refinements in sample prep and the core chemistry for the sequencing systems. The Invitae Partnership Could Unlock Major Long-Term Potential Back in January of this year, PacBio announced that it had agreed to a multi-year partnership with Invitae to take its core long-read sequencing technology and develop an ultra-high-throughput sequencing system, with the stated target of producing medically relevant whole genome sequences for less than $1,000. Long-read sequencing has long held great potential for diagnostic applications like oncology and rare diseases, but the cost of the technology has prevented the realization of that potential. If PacBio can deliver a system that generates below $1,000 whole genomes without compromising accuracy, it will be a major step forward in unlocking the full potential of long-read sequency and it will significantly expand PacBio’s long-term addressable market opportunities (adding several billions of dollars of possible revenue). Invitae will be subsidizing the R&D costs for this system, with the company getting preferential pricing in return. Importantly, PacBio will be able to sell the systems to other buyers, and it is not precluded from developing systems or related products for other diagnostic opportunities. A Large, Growing Opportunity Illumina has built a $3 billion-plus/year business on short-read sequencing, and while this technology is not going to go away, there are multiple markets where long-read sequencing could become the preferred option. Plant genomes, for instance, are full of long sequences of repeating genetic data that trip up short-read sequencing, but that’s not an issue for long-read sequencing. Likewise, there are meaningful accuracy advantages to long-read sequencing in animal genomics and bacterial sequencing – relevant to both food production and pharmaceutical research. In addition to the diagnostic opportunities in areas like oncology and rare diseases, long-read sequencing can also be used to detect and identify epigenetic modifications in DNA, which opens up major new areas of disease and treatment research. Between the improvements in the Sequel II platform and expanding investments in R&D and marketing, PacBio has a very real chance of increasing its market share to double-digits over the next five to six years and possibly to 20% or more by the end of the decade. That, in turn, could push revenue to $1 billion or more in 2030, with free cash flow margins in the 20% range. Wall Street’s Take Pacific Biosciences’ Moderate Buy consensus rating breaks down into 2 Buys and 1 Hold. Given the $53 average analyst price target, shares could surge 65% in the year ahead. (See Pacific Biosciences stock analysis on TipRanks) The Bottom Line PacBio has completely transformed itself in only a little over a year. The top-notch long-read sequencing technology was always there, but now, the company also has the executive leadership and the capital to maximize the potential of the technology, putting the company on a whole new competitive level. The shares do reflect that now, though, as the stock trades at around 25x 2023 sell-side revenue estimates. While there are other names with similar or higher multiples, the reality is that this is now a growth/momentum story driven by excitement over the long-term potential of long-read sequencing. Disclosure: On the date of publication, Stephen Simpson did not have (either directly or indirectly) any positions in the securities mentioned in this article. Disclaimer: The information contained herein is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities.

  • 3 Things to Watch in the Stock Market This Week
    Motley Fool

    3 Things to Watch in the Stock Market This Week

    PepsiCo is one of several big-name stocks set to announce earnings results over the next few trading days.